Epalrestat Tablets 50mg – For Laboratory Research Use Only

Epalrestat Tablets 50mg – For Laboratory Research Use Only

$2.00

Epalrestat Tablets provide 50mg of active compound per tablet. Manufactured by Hebei Ruisen Pharmaceutical Co., Ltd. Approved under H20253680. Intended strictly for laboratory research use only. Supports both bulk and individual orders.?For wholesale prices, other specifications and uses, please consult our staff?

EMI starting from $0.00/month - View Plans
Compare

Description

Epalrestat is an aldose reductase inhibitor (ARI) widely used in laboratory models investigating diabetic neuropathy, oxidative stress, and nerve conduction velocity. It plays a key role in research related to the polyol pathway, particularly under hyperglycemic conditions.

This formulation by Hebei Ruisen Pharmaceutical delivers 50mg per tablet and is ideal for in vitro and in vivo studies evaluating nerve protection and metabolic regulation in diabetic environments.

?? This product is for laboratory research use only. Not for human or veterinary consumption.


Product Specifications

ParameterDetails
Product NameEpalrestat Tablets
Generic NameEpalrestat
CAS Number82159-09-9
Molecular FormulaC??H??NO?S
Molecular Weight287.33 g/mol
Dosage FormTablet
Strength50mg per tablet
Packaging[To be confirmed – typically 10–30 tablets]
Approval NumberH20253680 (NMPA China)
Product Code86902606000418
ManufacturerHebei Ruisen Pharmaceutical Co., Ltd.
Storage ConditionsStore below 25°C in a cool, dry place
Intended UseLaboratory research only

Mechanism & Research Applications

Epalrestat inhibits aldose reductase, the key enzyme in the polyol pathway, which converts glucose to sorbitol. Under hyperglycemia, excess sorbitol contributes to nerve damage and oxidative stress. By blocking this conversion, epalrestat is valuable in exploring neuroprotective strategies for diabetic peripheral neuropathy (DPN).

It is commonly used in:

  • Diabetic neuropathy simulation in rodent models

  • Studies on nerve conduction velocity and oxidative stress

  • Aldose reductase inhibition profiling

  • Evaluation of glucose toxicity in endothelial cells

  • Synergistic studies with insulin sensitizers


Observed Effects in Research Models

Research has shown that epalrestat:

  • Improves nerve conduction velocity in diabetic rodents

  • Reduces sorbitol accumulation in nerves and tissues

  • Attenuates oxidative damage and improves antioxidant enzyme activity

  • Enhances vascular function in high-glucose conditions


Safety & Handling

  • Use Restriction: For research use only

  • Protective Equipment: Gloves, goggles, and lab coat recommended

  • Storage: Keep sealed and stored below 25°C, away from humidity

  • Disposal: Dispose in accordance with chemical safety protocols


Research Use Disclaimer

This product is strictly intended for laboratory research use only. It is not for human consumption or therapeutic application. Misuse may result in legal and health consequences. Handle with standard lab safety precautions.

Additional information

Weight1 kg
Dimensions26 × 23 × 26 cm

Reviews

There are no reviews yet.

Be the first to review “Epalrestat Tablets 50mg – For Laboratory Research Use Only”

Your email address will not be published. Required fields are marked *

Q1: Is this product safe for human intake?

No. These tablets are strictly for laboratory research purposes only and are not approved for therapeutic, diagnostic, or veterinary use.

Q2: What are the research applications of Epalrestat?

Epalrestat is commonly used in diabetic neuropathy models and studies focusing on oxidative stress and aldose reductase inhibition.

Q3: Do you support bulk orders?

Yes. We support wholesale and retail quantities and offer international shipping for qualified research labs and institutions.

Q4: Are COA and SDS available for this product?

Yes. You can request the Certificate of Analysis (COA) and Safety Data Sheet (SDS) along with your purchase.

Q5: Why is this product suitable for glucose-induced nerve damage research?

Epalrestat’s ability to inhibit aldose reductase makes it ideal for evaluating nerve protection, making it highly relevant in studies focused on diabetic neuropathy and glucose-induced cellular damage.

Q6:What is epalrestat used for?

Epalrestat is used in the treatment of diabetic nerve pain. Epalrestat is an aldose reductase inhibitor. It blocks the accumulation of sorbitol in cells, which has been related to causing diabetic nerve disease.

Q7:What is Epalrestat and Methylcobalamin used for?

Epalrestat+methylcobalamin is a combination medicine indicated for the management of diabetic neuropathy. Diabetic neuropathy is a condition in which nerve damage occurs due to high blood glucose levels. It primarily damages the nerves in the legs and feet.For Research Use Only

Q8:Epalrestat FDA approval

Epalrestat is available in several countries and well-tolerated by patients, but it is not yet approved for use by the Food and Drug Administration in the United States. The medication is currently in high-level clinical trials as part of the FDA's approval process.


EMI Options

Select at least 2 products
to compare